Newsroom
Investor Alert: ADMA Biologics Faces Securities Class Action Lawsuits
By KlickAnalytics Data Insights | June 30, 2026 08:04PM ET
Key Points
- Faruqi & Faruqi, LLP reminds ADMA Biologics investors of the securities class action lawsuit deadline on August 10, 2026
- Pomerantz Law Firm announces class action lawsuit against ADMA Biologics with upcoming deadlines
- Kahn Swick & Foti, LLC notifies investors of class action securities lawsuit deadline for ADMA Biologics
- The Schall Law Firm reminds investors of a class action lawsuit against ADMA Biologics for securities violations
- Lowey Dannenberg P.C. investigates ADMA Biologics for potential federal securities laws violations
A series of law firms have issued alerts and reminders to ADMA Biologics investors regarding ongoing class action lawsuits against the Company. Faruqi & Faruqi, LLP is one of the leading national securities law firms investigating potential claims against ADMA Biologics, reminding investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action. Those who suffered losses in ADMA Biologics between August 9, 2024 and March 25, 2026 are encouraged to contact partner James (Josh) Wilson directly to discuss their legal options.
Similarly, Pomerantz Law Firm has announced that a class action lawsuit has been filed against ADMA Biologics, advising investors who have faced losses on their investments to reach out to Danielle Peyton for further information. The firm reminds investors of the upcoming deadlines related to the lawsuit.
Kahn Swick & Foti, LLC, along with partner Charles C. Foti, Jr., has notified investors in ADMA Biologics of a class action securities lawsuit and the application deadline on August 10, 2026.
Moreover, The Schall Law Firm has encouraged investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 to contact the firm before the August 10, 2026 deadline. The firm is pursuing a class action lawsuit against the Company for violations of securities laws.
Furthermore, Lowey Dannenberg P.C., a top complex litigation law firm, is currently investigating ADMA Biologics for potential violations of federal securities laws. The firm is looking into allegations of misrepresentations about the Company's revenue sources that led to a significant stock plummet.
In light of these developments, it is crucial for ADMA Biologics investors to be aware of the ongoing legal actions and deadlines related to the securities class action lawsuits. Seeking legal counsel and understanding their rights is paramount for investors who may have suffered losses in the Company. Contacting the respective law firms mentioned in the alerts can provide investors with more information on how to proceed in this legal matter.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with